Editas Medicine
Editas Medicine Inc is an American clinical-stage biopharmaceutical enterprise headquartered in Cambridge, Massachusetts. The company specializes in the research, development, and commercialization of precision genomic medicines utilizing proprietary CRISPR gene editing technologies to treat severe genetic diseases, blood disorders, and inherited conditions. Principal revenue is currently earned through strategic pharmaceutical research collaborations, milestone payments, and capital financing arrangements. Editas Medicine Inc is publicly listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Editas Medicine.
- Legal name
- Editas Medicine Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding Editas Medicine
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)